Director, Quantitative Imaging or Imaging Biomarkers

Company Description

Image Analysis Group (IAG) is a trusted partner to life sciences companies, offering expertise in medical imaging and leveraging its DYNAMIKA platform to streamline clinical trials and standardize imaging data review. With a strong focus on radiological endpoints, IAG enhances trial efficiency, supports data‑driven decisions, and ensures clean data for regulatory submissions. By integrating AI into imaging and data processes, IAG maximizes patient recruitment speed and accelerates clinical outcomes. Over nearly two decades, IAG has successfully contributed to more than 700 trials across therapeutic areas such as oncology, immunology, rheumatology, obesity, and rare diseases.

Role Description

This is a full‑time role for a Director of Quantitative Imaging or Imaging Biomarkers, based in the London area, United Kingdom, with flexibility for partial remote work.

You will lead IAG’s non‑oncology imaging strategy, with primary focus on musculoskeletal (MSK), bone health, DXA and other specialty indications (e.g., rheumatology, orthopaedics, metabolic bone disease, rare disease and inflammatory conditions). This director‑level leader will combine a strong medical physics/quantitative imaging background with clinical trial experience to design imaging strategy, validate and oversee imaging endpoints, act as a senior sponsor‑facing expert, and build IAG’s reputation as a centre of excellence in MSK and specialty imaging.

Key Responsibilities

Scientific and translational leadership

• Define and lead IAG imaging strategy for MSK, DXA and specialty non‑oncology indications across phases I–IV and post‑marketing studies.
• Design and refine imaging endpoints and biomarker strategies aligned with programme objectives and Sponsors' needs.
• Work with IAG's Therapeutic Area Leads and help translating disease biology and mechanism of action into robust imaging readouts that support decision‑making in drug and device development.

Medical physics & quantitative imaging oversight

• Provide senior medical physics input on imaging protocol design, sequence/parameter optimisation, scanner standardisation and QA/QC for MRI, CT, DXA and related modalities.
• Together with IAG's team of Imaging specialists, lead scanner qualification and harmonisation programmes (including phantom work and site technical assessments) to ensure high‑quality, comparable data across vendors and geographies.
• Oversee development, validation and maintenance of quantitative analysis pipelines for specialty imaging, including performance assessment and documentation suitable for regulatory use.

Clinical trial and sponsor engagement

• Serve as a key scientific contact for sponsors on MSK and specialty imaging, from early opportunity/scoping through protocol design and study execution.
• Participate in or lead sponsor meetings, explaining and defending imaging strategies, endpoints and quantitative methods to clinical, biomarker and regulatory stakeholders.
• Partner with internal project management, data science and engineering teams to ensure imaging plans are feasible, scalable and aligned with timelines and budgets.

Team leadership & capability building

• Mentor and develop imaging project managers and indication‑focused imaging scientists within the MSK and specialty imaging space.
• Establish best practices, SOPs and training frameworks for quantitative MSK, DXA and specialty imaging across IAG.
• Contribute to workforce planning and recruitment to grow IAG's imaging function.

External visibility & innovation

• Represent IAG at relevant scientific meetings (e.g., EULAR, OARSI, ASBMR, ISMRM, ADA, EASL) and in consortia related to quantitative and specialty imaging.
• Lead or co‑author scientific publications, white papers and conference presentations on quantitative MSK and specialty imaging in clinical trials.
• Evaluate emerging imaging technologies (e.g., advanced reconstruction, radiomics, AI‑based quantification) and guide their integration into IAG offerings where they add clear value.

Qualifications

• Expertise in Nuclear Medicine, Radiology, or / and Medical Imaging
• Strong background in clinical trials
• Ability to lead multidisciplinary teams and manage cross‑functional collaborations
• Proficiency in image analysis software and familiarity with AI‑driven / automated imaging technologies
• Experience with clinical trials and understanding of regulatory requirements associated with imaging endpoints
• Strong analytical, problem‑solving, and communication skills
• Advanced degree in a relevant field such as Medicine, Radiology, or Biomedical Sciences
• Experience in therapeutic areas such as oncology, rheumatology, or neurology is an advantage

What IAG Offers

• You will partner directly with the CEO and senior leadership, influencing indication strategy, study design and productisation of imaging services rather than operating as a back‑office expert. Your voice will shape which opportunities we pursue and how we deliver them.
• You will oversee diverse, global trials in musculoskeletal, bone, rheumatology, rare disease and other specialty areas, with the scope to define and standardise how quantitative imaging is done across sponsors and studies. The work you design becomes the template for future programmes.
• You will have the mandate to grow and shape a dedicated quantitative and specialty imaging group—recruiting, mentoring and setting best practices—so that the function reflects your scientific standards and vision.
• Working alongside IAG’s engineering and AI teams, you can bring advanced reconstruction, quantitative pipelines and ML approaches from concept to operational reality, on real clinical trial data, at meaningful scale.
• We actively support conference presence, invited talks, leadership in working groups and publication of methods and results. You will be encouraged—and resourced—to be a visible voice in the international imaging and medical physics communities.
• Unlike academic or hospital systems, IAG offers short decision lines and the ability to move fast on ideas that make scientific and commercial sense. If you see a better way to do something, you will have the autonomy and support to implement it.
• We offer a competitive package with performance‑based incentives and the potential for equity participation, recognising that this role is central to IAG’s next phase of growth in imaging‑driven drug and device development.

#J-18808-Ljbffr